- freely available
HBV and HCV Therapy
AbstractOne year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.
Share & Cite This Article
Lampertico, P.; Aghemo, A.; Viganò, M.; Colombo, M. HBV and HCV Therapy. Viruses 2009, 1, 484-509.View more citation formats
Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV Therapy. Viruses. 2009; 1(3):484-509.Chicago/Turabian Style
Lampertico, Pietro; Aghemo, Alessio; Viganò, Mauro; Colombo, Massimo. 2009. "HBV and HCV Therapy." Viruses 1, no. 3: 484-509.
Notes: Multiple requests from the same IP address are counted as one view.